Bevonescein (ALM-488)
Nerve illumination during head & neck surgery and prostatectomy
Phase 3Active
Key Facts
Indication
Nerve illumination during head & neck surgery and prostatectomy
Phase
Phase 3
Status
Active
Company
About Alume Biosciences
Alume Biosciences is pioneering a precision surgery platform with its proprietary nerve-targeted fluorescent imaging agent, ALM-488. Founded in 2017 based on research from a Nobel Laureate, the company's technology aims to reduce iatrogenic nerve damage in complex surgeries, potentially improving functional outcomes for patients. With its lead program in Phase 3 trials and a planned NDA submission in 2026, Alume is positioned to address a significant unmet need in surgical oncology and beyond. The company has garnered support from key surgical thought leaders who recognize the transformative potential of intraoperative nerve visualization.
View full company profile